Using empagliflozin to improve heart function in patients with pulmonary arterial hypertension
Master - 2/2 Empaglifozin To Improve Right Ventricular Function in Pulmonary Arterial Hypertension
This study is looking at whether taking a daily medication called empagliflozin for 24 weeks can help improve heart function in people with pulmonary arterial hypertension (PAH), and it involves some tests to see how well your heart is working and how you feel overall.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10948583 on NIH RePORTER |
What this research studies
This research investigates the effects of empagliflozin, a medication taken daily for 24 weeks, on heart function in patients with pulmonary arterial hypertension (PAH). The study is a randomized, placebo-controlled trial conducted at three centers, where participants will undergo various assessments including cardiac imaging and quality of life evaluations. The primary goal is to determine if empagliflozin can enhance right ventricular function, measured through advanced imaging techniques. Patients will also be monitored for changes in exercise capacity and other health indicators throughout the trial.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension who meet specific health criteria.
Not a fit: Patients who do not have pulmonary arterial hypertension or those with contraindications to empagliflozin may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved heart function and quality of life for patients suffering from pulmonary arterial hypertension.
How similar studies have performed: Previous research has shown promising results with similar medications in improving heart function, making this approach both relevant and potentially impactful.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Gassman, Jennifer J — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Gassman, Jennifer J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.